Across the UK and much of Europe, patients waiting for an initial psychiatric assessment routinely face delays of six months to a year and a half. It's a capacity crisis that Copenhagen-based Aisel Health believes can be eased, at least in part, by automating the mountains of paperwork that consume psychiatrists' limited time.
The startup, founded in 2024, disclosed in March 2025 that it had closed a pre-seed funding round led by Rockstart Emerging Tech Fund Europe I and Ada Ventures, with backing from Loyal VC and several angel investors including Ulla Sommerfelt and Peter Troensegaard Kruse Jensen. Aisel declined to specify the amount raised.
What the company is building is a clinical operating system designed specifically for psychiatric clinics. The platform tackles workflows at three stages: before a consultation, it collects patient information through AI-driven conversations; during the session, it captures notes; and afterward, it drafts documentation ranging from benefits reports to court filings and Mental Health Act paperwork. The system was built with GDPR compliance and end-to-end encryption as foundational features, targeting the UK and EU markets where regulatory scrutiny of health data runs deep.
Pilots and Partnerships
Aisel's software is currently being tested in UK clinics, though the company has not released details on how many sites are participating or what early results show. In Denmark, the startup holds a more formal collaboration with Psykiatrisk Center Sct. Hans and the University of Southern Denmark under a mental health innovation grant from Erhvervsfyrtårn Life Science, awarded on June 11, 2025, and worth up to DKK 3 million (roughly $430,000). That project, which carries the Danish title "Dual Diagnose Capacity gennem brug af GenAI," ran from March 1, 2025, to March 1, 2026.
Aisel also secured a multi-year Innofounder grant from Innovationsfonden, Denmark's national innovation fund, during the same period.
A product update introduced in March added what the company calls AI Conversations, a feature intended to facilitate patient dialogues between scheduled appointments. LinkedIn data from July 2026 suggested the company employed roughly 19 people, though startup headcounts can shift quickly.
Who's Behind It
Co-founder and CEO Augusta Klingsten Peytz came to Aisel from a background in venture capital, where she concentrated on mental health investments, and holds an MBA from INSEAD. Her co-founder, Christian R. Houen, serves as chief product officer. Houen studied at Copenhagen Business School and previously worked in healthtech at 3Shape, a dental technology company, according to coverage by Danish outlet TechSavvy.
The startup's advisors include Rikke Esbjerg, the former CEO of health information site Netdoktor, and Nicolas Hansen, a chief physician in psychiatry. TechSavvy's reporting on the fundraise quoted Michael Bjørnlund, managing partner for emerging tech at Rockstart, saying in Danish that the Aisel team "combines strong competencies" to navigate toward the right product-market fit. Peytz, in the same article, outlined the company's vision: "to create a world where AI and psychiatrists work together to make mental health more accessible."
Ada Ventures participated through its Danish Ada Angels program, team member Jasmin Thomas noted in a post at the time.
A Crowded, U.S.-Dominated Field
Aisel is entering a clinical documentation market where American companies have pulled in enormous sums. Abridge, which offers AI-powered clinical note-taking, raised roughly $300 million in a Series E round in June of last year, according to STAT News. Suki provides ambient clinical intelligence across more than 100 specialties, psychiatry among them. Osmind, meanwhile, focuses on electronic health records and revenue cycle management specifically for interventional psychiatry practices.
The European regulatory environment may offer Aisel some breathing room. NHS England's performance data from January 2026 continued to show strain on mental health access targets, and Denmark's health authority published an analysis of psychiatric wait times in April of last year. Aisel is positioning its compliance infrastructure—UK and EU data residency, GDPR adherence, encryption standards—as a key differentiator for healthcare buyers navigating Europe's stricter data regimes.
In a March update, the company articulated a design philosophy: "AI should not change how psychiatry works." The intent, Aisel says, is to fit existing clinical workflows rather than upend them. Whether that approach will prove sufficient to carve out meaningful market share against better-funded U.S. competitors remains an open question, one that will likely hinge on how quickly European clinics are willing to adopt AI tools in a field where the stakes of error are particularly high.
